Clinical aspects of ifosfamide-induced encephalopathy

被引:0
|
作者
Weise, J [1 ]
Kohler, G [1 ]
Muller, J [1 ]
机构
[1] Univ Greifswald, Frauenheilkunde & Geburtshilfe Klin & Poliklin, D-17487 Greifswald, Germany
关键词
encephalopathy; ifosfamide; CNS-toxicity; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the application of ifosfamide, one must be prepared for an ifosfamide-induced encephalopathy. The aim of our investigation was to determine the incidence of this side-effect and to describe its risk factors and the clinical management as well. Among 688 chemotherapy courses consisting of carboplatin and ifosfamide, we have observed an ifosfamide encephalopathy in 13 cases (1.89%) which was always associated with the risk factors alcohol anamnesis, hypalbuminemia, liver-or kidney dysfunction or a large tumor in the pelvis. Within the criteria of an intensive observation, the therapy consisted mainly of a forced diuresis in combination with a correction of the fluid and electrolyte balance. First experiences with the administration of methylene blue are reported. Using an ifosfamide dosage of 2 g/m(2) body surface area on day 1-3, and in consideration or exclusion of the above mentioned risk factors severe encephalopathies can be widely avoided.
引用
收藏
页码:129 / 132
页数:4
相关论文
共 50 条
  • [21] Ifosfamide-induced psychosis
    Hernández, R
    Juan, O
    Alberola, V
    ACTA ONCOLOGICA, 2004, 43 (01) : 119 - 120
  • [22] Glucose infusions - Possible effective treatment option in Ifosfamide-induced encephalopathy
    Kellner, O
    Dempke, W
    Schmoll, HJ
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 124 (37) : 1086 - 1087
  • [23] Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy
    Gharaibeh, Eyad Z.
    Telfah, Mohammad
    Powers, Benjamin C.
    Salacz, Michael E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) : 1784 - 1786
  • [24] Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy
    Durand, J. -P.
    Gourmel, B.
    Mir, O.
    Goldwasser, F.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 808 - 809
  • [25] IFOSFAMIDE-INDUCED HYPERPIGMENTATION
    YULE, SM
    PEARSON, D
    CRAFT, AW
    CANCER, 1994, 73 (01) : 240 - 240
  • [26] IFOSFAMIDE-INDUCED NEPHROTOXICITY
    ROSSI, R
    RATH, B
    ULLRICH, K
    EHRICH, JHH
    MONATSSCHRIFT KINDERHEILKUNDE, 1993, 141 (07) : 594 - 601
  • [27] Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®)
    Chambord, Jeremy
    Henny, Fabien
    Salleron, Julia
    Hombourger, Benoit
    Lider, Pauline
    Vigneron, Jean
    Demore, Beatrice
    Vallance, Catherine
    Rios, Maria
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (03) : 372 - 380
  • [28] Reversible ifosfamide-induced encephalopathy with bursts of triphasic waves responsive to levetiracetam
    Zubko, Luis Eduardo Borges de Macedo
    Brandao, Lucas Altoe
    Disserol, Caio Cesar Diniz
    Nascimento, Igor Ibrahim
    de Paola, Luciano
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2024, 82 (11) : 2 - 3
  • [29] Differences in ifosfamide-induced encephalopathy after use of two different formulations
    Beau-Salinas, F.
    Bousquet-Plichon, C.
    De la Bretonniere, M. Ertault
    Jourdain, A.
    Andre, V.
    Vrignaud, L.
    Jonville-Bera, A. P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 31 - 31
  • [30] Recurrent ifosfamide-induced hyponatraemia
    Kirch, C
    Gachot, B
    Germann, N
    Blot, F
    Nitenberg, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (14) : 2438 - 2439